BSE · 524516
Bacil Pharma Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1 Cr with net profit ₹2 Cr — a 125.93% net margin, versus 61.09% the period before.
Shareholding
As of 2026-06-30
- Public100%
7,326 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 5.8× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ST-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
- 52-week range spans 5.8× (₹10.65 to ₹61.8) — an unusually wide band.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #25 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,49,939 Cr | 83.89 | 14.91 | 15.32% | 26.05% |
| Neuland Laboratories Ltd. | ₹30,497 Cr | 61.27 | 16.28 | 19.42% | 20.99% |
| Acutaas Chemicals Limited | ₹28,354 Cr | 73.42 | 17.15 | 21.54% | 26.42% |
| Jubilant Pharmova Ltd. | ₹16,342 Cr | 42.12 | 2.3 | 5.62% | 4.11% |
| Aarti Drugs Ltd. | ₹3,986 Cr | 20.69 | 2.57 | 12.58% | 7.14% |
| SMS Pharmaceuticals Ltd. | ₹3,895 Cr | 38.05 | 4.96 | 12.98% | 11.41% |
| Hikal Limited | ₹2,891 Cr | 68.15 | 2.41 | 3.03% | -1.96% |
| Beta Drugs Limited | ₹2,309 Cr | 50.65 | 9.4 | 16.95% | 11.11% |
| NGL Fine Chem Limited | ₹1,671 Cr | 29.21 | 5.08 | 14.62% | 10.67% |
| Fermenta Biotech Ltd. | ₹1,427 Cr | 26.08 | 3.51 | 17.67% | 11.68% |
| Bacil Pharma Ltd.(this company) | ₹27 Cr | 40.39 | 1.06 | 6.27% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashBacil Pharma Ltd. is listed with a market capitalization of Rs 50 Cr. The company reported annual revenue of Rs 0.66 Cr in March 2025.
Positives
- +The debt-to-equity ratio is low at 0.01.
- +Annual net profit turned positive at Rs 0.40 Cr in March 2025.
- +Annual revenue increased to Rs 0.66 Cr in March 2025 from Rs 0.13 Cr in March 2024.
Negatives
- −The profit margin is 0%, indicating no reported profit as a percentage of revenue.
- −Promoter shareholding is 0% as of June 30, 2026.
- −DII and FII holdings are both 0% as of June 30, 2026.
- −Quarterly revenue has been Rs 0 Cr for several quarters, including Dec 2024, Mar 2025, Jun 2025, Sept 2025, Dec 2025, and Mar 2026.
- −The company's PE ratio is 32.05, while the book value is Rs 17.55.
Financial performance
Bacil Pharma Ltd. reported revenue of Rs 0.66 Cr in March 2025. This marks a positive shift from previous years, where revenue was Rs 0.13 Cr in March 2024 and Rs 0.11 Cr in March 2023. The company also turned profitable in March 2025 with a net profit of Rs 0.40 Cr, following losses of Rs -0.06 Cr in March 2024 and Rs -0.10 Cr in March 2023. The EPS for March 2025 was 0.64.
Profitability & returns
In March 2025, Bacil Pharma Ltd. reported a Return on Equity (ROE) of 6.27% and a Return on Capital Employed (ROCE) of 3.99%. The profit margin for the latest available annual period was 0%. The company's EPS was Rs 1.08.
Balance sheet
The company has a low debt-to-equity ratio of 0.01. The book value per share is Rs 17.55.
Ownership & pledges
As of June 30, 2026, public shareholding in Bacil Pharma Ltd. stands at 100%. There is no promoter holding (0%) and no institutional holding (0%). The number of shareholders was 7,326. There are no shares pledged by promoters.
Data as of — price: 2026-09-10 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.